Mein Warenkorb

IL-8

IL-8 Molekülinformation

Englischer NameInterleukin-8Anzahl der inverkehr gebrachten Arzneimittel1
Anzahl der klinischen Arzneimittel6Target-AliasIL8/NAP1 form VI,T-cell chemotactic factor,GCP/IL-8 protein III,IL8/NAP1 form II,GCP/IL-8 protein II,(Ala-IL-8)77,Emoctakin,IL8/NAP1 form IV,LYNAP,IL8/NAP1 form III,IL8/NAP1 form V,GCP/IL-8 protein I,Neutrophil-Activating Peptide 1,Interleukin 8,GCP-1,MDNCF,NAP-1,IL8,Beta Endothelial Cell-Derived Neutrophil Activating Peptide,Lung Giant Cell Carcinoma-Derived Chemotactic Protein,Lymphocyte Derived Neutrophil Activating Peptide,Alveolar Macrophage Chemotactic Factor I,Tumor Necrosis Factor-Induced Gene 1,Small Inducible Cytokine Subfamily B, Member 8,Beta-Thromboglobulin-Like Protein,GCP1,LECT,LUCT,NAP1,IL-8,Interleukin-8,AMCF-I,SCYB8,Neutrophil-Activating Protein 1,B-ENAP,3-10C,K60,TSG-1,C-X-C Motif Chemokine Ligand 8,Monocyte-Derived Neutrophil Chemotactic Factor,Monocyte-Derived Neutrophil-Activating Peptide,Granulocyte Chemotactic Protein 1,Chemokine (C-X-C Motif) Ligand 8,(Ser-IL-8)72,Neutrophil-activating factor,MDNCF-c,C-X-C motif chemokine 8,Lymphocyte-derived neutrophil-activating factor,Protein 3-10C,IL-8(1-77),NAF,GCP/IL-8 protein VI,GCP/IL-8 protein IV,IL8/NAP1 form I,MONAP,MDNCF-b,GCP/IL-8 protein V,CXCL8
Höchste Forschungs- und EntwicklungsphaseApproved
Englischer NameInterleukin-8
Target-AliasIL8/NAP1 form VI,T-cell chemotactic factor,GCP/IL-8 protein III,IL8/NAP1 form II,GCP/IL-8 protein II,(Ala-IL-8)77,Emoctakin,IL8/NAP1 form IV,LYNAP,IL8/NAP1 form III,IL8/NAP1 form V,GCP/IL-8 protein I,Neutrophil-Activating Peptide 1,Interleukin 8,GCP-1,MDNCF,NAP-1,IL8,Beta Endothelial Cell-Derived Neutrophil Activating Peptide,Lung Giant Cell Carcinoma-Derived Chemotactic Protein,Lymphocyte Derived Neutrophil Activating Peptide,Alveolar Macrophage Chemotactic Factor I,Tumor Necrosis Factor-Induced Gene 1,Small Inducible Cytokine Subfamily B, Member 8,Beta-Thromboglobulin-Like Protein,GCP1,LECT,LUCT,NAP1,IL-8,Interleukin-8,AMCF-I,SCYB8,Neutrophil-Activating Protein 1,B-ENAP,3-10C,K60,TSG-1,C-X-C Motif Chemokine Ligand 8,Monocyte-Derived Neutrophil Chemotactic Factor,Monocyte-Derived Neutrophil-Activating Peptide,Granulocyte Chemotactic Protein 1,Chemokine (C-X-C Motif) Ligand 8,(Ser-IL-8)72,Neutrophil-activating factor,MDNCF-c,C-X-C motif chemokine 8,Lymphocyte-derived neutrophil-activating factor,Protein 3-10C,IL-8(1-77),NAF,GCP/IL-8 protein VI,GCP/IL-8 protein IV,IL8/NAP1 form I,MONAP,MDNCF-b,GCP/IL-8 protein V,CXCL8
Anzahl der inverkehr gebrachten Arzneimittel1
Anzahl der klinischen Arzneimittel6
Höchste Forschungs- und EntwicklungsphaseApproved

IL-8 Produktliste

  • Attribut

    Protein (5)Kits (3)

  • Produktbibliothek

    Online (7)In Forschung (1)

  • Spezies

    Human (7)Rhesus macaque (1)

  • Etikett

    His Tag (2)Fc Tag (1)His Tag & Avi Tag (1)- (3)Tag Free (1)

  • Marker

    Unconjugated (4)Biotin-labeled (1)- (3)

IL-8 Molekülhintergrund

Interleukin 8 (IL8 or chemokine (C-X-C motif) ligand 8, CXCL8) is a chemokine produced by macrophages and other cell types such as epithelial cells, airway smooth muscle cells and endothelial cells. There are many receptors on the surface membrane capable of binding IL-8, the most frequently studied types are the G protein-coupled serpentine receptors CXCR1 and CXCR2. Expression and affinity for IL-8 differs between the two receptors (CXCR1 > CXCR2). IL-8(6-77) has a 5-10-fold higher activity on neutrophil activation, IL-8(5-77) has increased activity on neutrophil activation and IL-8(7-77) has a higher affinity to receptors CXCR1 and CXCR2 as compared to IL-8(1-77), respectively.

IL-8 Molekülalias

CXCL8,GCP1,IL8,LECT,LUCT,LYNAP,MDNCF,MONAP,NAF,NAP-1

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
EnsereptidePXL-01Phase 3 ClinicalPromore PharmaCicatrix; Post-surgical adhesions; Tissue Adhesions
Details
CinainuPhase 3 ClinicalLegacy Healthcare (Switzerland) SaAlopecia Areata
Details
Sodium HypochloritePhase 3 ClinicalCystic Fibrosis; Dental Pulp Necrosis; Fibrosis; Infections; Pain; Pain, Postoperative; Pulpitis
Details
AdakitugBMS-986253; MDX-018Phase 2 ClinicalBristol-Myers Squibb Company, Genmab A/S, Medarex IncCarcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Coronavirus Disease 2019 (COVID-19); Hematologic Neoplasms; Melanoma; Myelodysplastic Syndromes; Neoplasms; Prostatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck
Details
AMY-109AMY-109; AMY109Phase 2 ClinicalChugai Pharmaceutical Co LtdEndometriosis; Solid tumours
Details
AC-701AC-701Phase 2 ClinicalTwi Pharmaceuticals IncExanthema; Rosacea
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
Mouse monoclonal antibody against human interleukin-8 creamApprovedDalian Asia Space Pharmaceutical Co Ltd, Dongguan Hongyuan Yishi Biotechnology Pharmaceutical Co Ltd恩博克Mainland ChinaEczema; PsoriasisDalian Asia Space Pharmaceutical Co Ltd2001-04-10Eczema; Psoriasis
Details
  • Molekülinformation
  • Produktliste
  • Inverkehr gebrachte Arzneimittelinformation
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns